Understand the source comparison
Do Peptides Help with CIRS? Comparison Across Evidence Levels
Thymalin T-regulatory cell enhancement, thymic function restoration Increases T-reg populations by 30–40% in autoimmune trials; addresses T-reg suppression seen in CIRS Randomised trials in autoimmune thyroiditis and RA (90+ patients) 10mg subcutaneous, 10–20
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymalin
- T-regulatory cell enhancement, thymic function restoration
- Increases T-reg populations by 30–40% in autoimmune trials; addresses T-reg suppression seen in CIRS
- Randomised trials in autoimmune thyroiditis and RA (90+ patients)
- 10mg subcutaneous, 10–20 day cycles
- Strongest mechanistic fit for immune rebalancing in CIRS; human data exists but not CIRS-specific
- BPC-157
- TNF-alpha/IL-6 reduction, gut barrier repair, angiogenesis
- Reduces pro-inflammatory cytokines by 40–50% in rodent colitis; promotes tissue healing in gut and CNS
- Small human trials in IBD and tendinopathy; no CIRS trials
- 250–500mcg subcutaneous twice daily
- Strong preclinical data; mechanism addresses gut and neuroinflammation but lacks CIRS-population trials
- Cerebrolysin
- BDNF upregulation, neuroprotection, reduced neuroinflammation
- Increases BDNF and protects against cytokine-mediated neurotoxicity in stroke models
- 30+ RCTs in stroke, TBI, vascular dementia (1000+ patients)
- 30ml IV infusions, 10–20 day cycles
- Best evidence for cognitive dysfunction; mechanism overlaps with CIRS brain fog but not tested in CIRS cohorts
- KPV
- MSH-mimetic, anti-inflammatory signaling in gut and CNS
- Reduces colonic inflammation and restores barrier function in UC models; directly addresses MSH deficiency
- Minimal human data; primarily rodent colitis studies
- 500mcg–1mg subcutaneous or oral
- Directly targets MSH suppression in CIRS but evidence is almost entirely preclinical